Instalab
Praluent · 75mg or 150mg · alirocumab autoinjector

LDL cut in half. Heart attacks and deaths reduced.

Praluent® (alirocumab) is a PCSK9 inhibitor that cuts LDL 50–60% on top of a statin and reduced major cardiovascular events 15% post-heart-attack. Prescription, refills, and physician follow-up included.

50–60%Median LDL reduction
15%Reduction in MACE (ODYSSEY OUTCOMES)
15%All-cause mortality reduction
Praluent Prescription Review
Praluent · 75mg or 150mg autoinjector · every 2 weeks or monthly
Licensed US physician review
12,000+ patients treated
Available in all 50 states
Ongoing physician follow-up
How it works

From questionnaire to first injection.

No clinic visits. A licensed physician reviews your case, checks what you'll pay, and writes the prescription. We file prior authorization and coordinate the pharmacy.

Step 1

2-minute questionnaire

Tell us about your history, prior statin treatments, lipids, and cardiovascular goals.

Step 2

Physician review

A licensed physician evaluates your eligibility, usually within 1 business day, and reaches out if anything else is needed.

Step 3

Cost check and prior authorization

We check your insurance coverage and file prior authorization. If you self-pay, the Regeneron co-pay card can substantially reduce out-of-pocket costs.

Step 4

Prescription sent, first injection

Your Praluent pen is sent to your preferred pharmacy. We walk you through self-injection and check in after your first dose.

Pricing

What you'll actually pay.

Two line items: Instalab Membership and the Praluent medication itself.

Instalab Membership

Physician oversight, prior authorization, lab follow-up, ongoing care

$—/mo

Praluent (alirocumab autoinjector)

Brand-name only, billed by pharmacy

Cash price$441–525/monthCash price without insurance
With insurance$25–100/monthTypical copay, if covered

Why pay a membership fee? Praluent needs a physician who knows the drug, handles prior authorization with your insurance, and tracks your lipids over time. Membership covers visits, paperwork, and ongoing care. Lab costs are billed separately.

Will my insurance cover Praluent?

Most commercial plans cover Praluent for patients with one of: familial hypercholesterolemia, established cardiovascular disease (prior heart attack, stroke, or stented artery), or documented statin intolerance. Medicare Part D typically covers it under the same criteria. We check your plan and file the prior authorization either way. If approval is denied or insurance does not apply, the Regeneron co-pay card can substantially reduce out-of-pocket cost for eligible commercially insured patients.

Why membership

Praluent works. Staying on it takes ongoing care.

It needs a physician who knows the drug, files prior authorization, and tracks lipids to confirm it is doing its job. Here's how our team handles that for you.

  1. Week 1Day 1–5

    Physician evaluation and prescription

    A licensed physician reviews your history and labs, confirms Praluent is right for you, and writes the prescription. In parallel, we file prior authorization with your insurance and check copay-assistance eligibility.

  2. Week 2Day 6–14

    First injection at home

    Your Praluent pen ships from your preferred pharmacy. We walk you through the first injection and check in the next day.

  3. Week 6–8

    Confirm it's working

    Recheck LDL and ApoB at a lab near you, and your physician reviews the results with you. Labs are billed separately.

  4. OngoingMonth 3+

    Ongoing care and renewals

    Your physician tracks lipids over time and adjusts the plan as your numbers evolve. We keep your prescription and prior authorization active so you don't lose a year of progress to paperwork.

Without membership

Schedule a cardiology visit. Wait months. Hope they know the drug. Track down prior authorization yourself. Book and chase your own labs.

With Instalab

2-minute questionnaire. Physician review within 1 business day. Insurance and copay assistance handled. Lab reminders built in.

About the medication

A pen injection every 2 weeks (or monthly).

Praluent comes in a pre-filled autoinjector pen at 75mg or 150mg. Most patients start at 75mg every 2 weeks; some switch to 300mg monthly for convenience or to 150mg every 2 weeks if more reduction is needed.

  • Takes about 20 secondsThe autoinjector does the work. Press, hold, done. Stomach, thigh, or upper arm.
  • Every 2 weeks or once monthly75mg or 150mg every 2 weeks, or 300mg once monthly. Your physician picks the schedule based on LDL response.
  • Lab recheck recommendedRecheck LDL and ApoB at 4 to 8 weeks. Labs are billed separately.
  • Ongoing physician supportYour care team is a message away. Reach out for injection technique, refills, or insurance issues.
Why Praluent

Cardiovascular mortality reduction on top of a statin.

Praluent (alirocumab) is a monoclonal antibody that binds PCSK9, the protein that destroys LDL receptors on liver cells. With more receptors active, the liver pulls more LDL out of your blood. In the ODYSSEY OUTCOMES trial, Praluent reduced major cardiovascular events by 15% and reduced all-cause mortality by 15% in patients after an acute coronary syndrome — making it one of two PCSK9 inhibitors with both event and mortality data on top of a statin.

  • 50 to 60% LDL reductionIn the pivotal trials, Praluent dropped LDL by 50 to 60% at 24 weeks on top of statin therapy.
  • 15% reduction in major cardiovascular eventsODYSSEY OUTCOMES randomized 18,924 patients with recent acute coronary syndrome to Praluent or placebo on top of high-intensity statin. Over a median 2.8 years, Praluent reduced the composite of CHD death, MI, ischemic stroke, or unstable angina by 15%, with a 15% reduction in all-cause mortality.
  • A non-statin path to very low LDLFor patients who need more LDL reduction than statins alone can deliver, or who cannot tolerate higher-intensity statins, Praluent is one of the two PCSK9 inhibitors with strong outcome data.

The ODYSSEY OUTCOMES trial

Published in NEJM in 2018, ODYSSEY OUTCOMES randomized 18,924 patients 1 to 12 months after acute coronary syndrome to alirocumab or placebo on top of high-intensity statin therapy. Over a median 2.8 years, alirocumab reduced the primary composite (CHD death, MI, ischemic stroke, or unstable angina requiring hospitalization) by 15% and reduced all-cause mortality by 15%.

18,924
Patients post-ACS randomized
15%
Reduction in major CV events
15%
Reduction in all-cause mortality

Praluent is a prescription medicine. Important safety information applies. Side effects include injection-site reactions and cold-like symptoms. Serious side effects are uncommon.

Ready when you are

Cut LDL. Cut events. Cut deaths.

Answer the questionnaire. A physician reviews your case and, if Praluent is appropriate, prescribes it. We file prior authorization and handle refills.

No commitment to treatment.